The AAP’s guidelines on lipid screening for children raise concerns about the fundamental purpose of prevention and its role in balancing individual autonomy with the benefits of society at large.
Drivers, physicians, and motor vehicle agencies all have some responsibility in reducing the number of fatal traffic accidents caused by driver sleepiness.
Two physicians give an overview of the iPledge program and discuss the problematic aspects of the program for physicians who prescribe isotretinoin and their patients.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.